“We are developing orally available, small molecules that modulate the immune system in a new way -- through serotonin receptors on immune cells. By blocking certain serotonin receptors on activated immune cells, our compounds curtail inappropriate immune cell proliferation, a key component of autoimmune/inflammatory conditions, without harming resting cells.
In just two years, our new chemical entity synthesis and screening program has yielded two compounds with strong clinical potential. C-027, orally administered, is safe and efficacious pre-clinically in two pulmonary indications—asthma and pulmonary arterial hypertension. The compound inhibits airway hyper-responsiveness in an allergic mouse model for asthma, and in ex vivo, human lung slices made hyper-responsive with cytokines or via mast cell activation. C-027 also significantly decreases pulmonary arterial pressure in a standard rat model for pulmonary hypertension. ”
Immune Control is a first-mover and the leader in serotonin-based immunotherapeutics. This new technology blocks specific serotonin receptors on activated immune cells involved in pathologic autoimmune responses. Because our approach eliminates the subset of cells producing disease while sparing normal immune cells, it holds the promise of treating the causative elements of autoimmunity with a more favorable side effect profile than traditional treatments.